Estimation Of Potential Gain In Quality Of Life From Early Detection Of Cervical Cancer

Published Apr 28, 2014
Tainan, Taiwan - Each year, about 528,000 new cases of cervical cancer are reported worldwide. In Taiwan, a screening program exists for early detection, which can save life-years for those individuals who are affected, but the effect on quality of life still remains to be quantified. In the article, “Estimation of Potential Gain in Quality of Life from Early Detection of Cervical Cancer,” published in Value in Health, investigators abstracted data of 22,543 new cases of invasive cervical cancer (ICC) from the Taiwan National Cancer Registry to estimate the lifetime survival function, as well as a consecutive, cross-sectional sample of 421 patients with ICC or carcinoma in situ (CIS) to measure the QOL. The ratio of QOL score functions for ICC and CIS patients were summed up over lifetime to obtain the duration of suffering from unsatisfactory HRQL. Jung-Der Wang MD, ScD, from the National Cheng Kung University Medical College and Hospital, lead author of the study, states, “In comparison with invasive cervical cancer, early detection of cervical neoplasm at the pre-cancer (carcinoma in situ, CIS) stage not only avoids 6.48 years of life loss, but also prevents reduction in HRQL in the long-run, leading to HRQL gains in the physical (1.71 years) and psychological (0.25 years) domains, as well as sexual life (1.47 years).”

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision-makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

Follow Value in Health on Twitter: @ISPORJournals

For more information: www.ispor.org

Related Stories

New Research Collection Reveals How Artificial Intelligence Is Reshaping Health Economics

Nov 6, 2025

The PhRMA Foundation and ISPOR announced the publication of a special themed section of research papers that explores the dynamic intersection of artificial intelligence (AI) and health economics and outcomes research (HEOR).

ISPOR Announces 2025 Health Economics and Outcomes Research Award Honorees

Oct 20, 2025

ISPOR announced the recipients of its 2025 Health Economics and Outcomes Research (HEOR) Scientific and Leadership Awards. ISPOR Scientific Awards are designed to foster and recognize excellence and outstanding achievement in HEOR and its Leadership Awards recognize excellence and outstanding leadership in the field.

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×